Chronic myelogenous leukemia in Libya

Mehdi, Itrat; Kashmiri, Arshad Hussain

doi:10.4103/2278-330x.96500

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, an uncertainty remains in the interpretation of the chronic phase (CP) of this cohort. According to the ELN criteria [ 8 ], all 30 patients were in CP at the time of diagnosis, but given the fact that no karyotyping was performed—due to the lack of this technique in the routine diagnostic in Tanzania—and additional chromosomal aberrations at diagnosis define the accelerated phase according to the WHO [ 10 ]. One could speculate that some patients of this cohort were underdosed with Imatinib and, hence, achieved a poor outcome.…”

Section: Discussionmentioning

confidence: 99%

“…A retrospective data analysis from Ethiopia came to the same conclusion, as CML was the most common leukaemia entity amongst 67 cases of haematologic malignancies at a single centre [ 9 ]. CML as a very common entity in haematologic malignancies is also described for Libya in 2012 by Mehdi et al [ 10 ]. Remarkably, this study reports the fact that Black Africans are significantly more affected than non-Black Libyans.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment

Henke

Mapendo

Mkwizu

et al. 2020

ecancer

View full text Add to dashboard Cite

Background Data about haematologic malignancies from Tanzania are sparse. African studies show that chronic myeloid leukaemia (CML) is the most common leukaemia, and registry data display a lower mean age at diagnosis. Prognosis is generally good with tyrosine kinase inhibitors, but the molecular response of Imatinib treatment has never been studied in East Africa, and the outcome remains unknown. This study assessed the early molecular response (MR) as a predictor for long-term outcome and barriers to access treatment. Methods A case series of patients with CML from Northern Tanzania documented demographics and laboratory and clinical findings at diagnosis and after 3 months. The regression analysis has been performed on early MR and clinical and demographic variables using the χ2-test. The barriers of potential treatments have been assessed. Results A total of 30 patients have been analysed. The mean age was 41 years. All patients had splenomegaly, whereas 16 had hepatomegaly. Complete haematologic response was achieved in 16 and early MR in 9 patients. Hepatomegaly was positively correlated with unfavourable early MR. The average kilometre from home to hospital was 282 km (5–1,158 km). Travel expenses and time investments pose an impediment to treatment. Conclusion Patients are younger, and early MR rates are lower compared to other studies. The finding of hepatomegaly as a risk factor for unfavourable early MR was described previously in West Africa. Adherence to therapy is high in the first months of treatment. Furthermore, research is needed to understand the poor MR and the common presentation of hepatomegaly. Outreach clinics might be a solution to reduce impediments to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment

Henke

Mapendo

Mkwizu

et al. 2020

ecancer

View full text Add to dashboard Cite

show abstract

General Oncology Care in Oman

Mehdi

Farsi

Bahrani

et al. 2022

Cancer in the Arab World

Self Cite

View full text Add to dashboard Cite

The Sultanate of Oman is located on the Arabian Peninsula and is part of Western Asia. Oman has a relatively young population. The economy is based on oil, agriculture, fishing, and overseas trading. Oman spends around 3% of its GDP on health care. Omani nationals have free access to public healthcare. Due to increased incomes and changing lifestyles, the rate of Non-Communicable Diseases (NCD) including cancer is rising. This is slowly saturating the system and increasing health care costs. Cancer is now the third leading cause of mortality. The age-adjusted annual incidence of cancer ranges from 70 to 110 per 100,000 population. Oman has an operational national NCD action plan. This multi-sectoral plan was launched in 2018 and focuses on the government approach in addressing NCDs including cancer, highlighting the prevention and control strategies. There is an integrated cancer care service, cancer registry, and cancer control program; under the auspices of the Directorate general of Non-communicable diseases—Ministry of Health. Oman has envisioned an ambitious long-term health care plan called “Health care Vision 2050”, which includes the development and progression of cancer care services as well. This plan has an emphasis on development, patient empowerment, public awareness, health education, integration and accessibility of services, screening, and early detection, public–private partnership, indulgence for NGOs, research, and capacity building.

show abstract

Chronic myelogenous leukemia in Libya

Cited by 2 publications

References 2 publications

Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment

Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment

General Oncology Care in Oman

Contact Info

Product

Resources

About